Sermorelin, tesamorelin and CJC-1295: what is the difference?

What do the three share?

Sermorelin, tesamorelin and CJC-1295 are related to growth-hormone-releasing hormone (GHRH), which signals the pituitary to release growth hormone. Their sequences and formulations differ. A shared pathway is a reason to compare their questions, not a reason to assume the same duration, benefit or harms. Ipamorelin is commonly mentioned nearby, but acts at a different, ghrelin-related receptor. See CJC-1295 and ipamorelin.18

How does sermorelin’s history differ?

The discontinued US Geref products had diagnostic and paediatric growth-deficiency uses. A small adult study measured strength and body composition, and another tested cognition; neither history establishes an adult anti-ageing indication. The sermorelin profile follows those studies and the historic FDA decision.123

What is different about tesamorelin?

Egrifta WR is a named US tesamorelin medicine indicated for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight-loss management. A placebo-controlled trial in this population measured visceral fat, the fat surrounding internal organs. A separate trial in older adults studied cognitive tests. Neither result automatically transfers to sermorelin, CJC-1295 or a different population. See the visceral-fat study.456

The US Egrifta WR label lists pregnancy, active cancer, disruption of the hypothalamic–pituitary axis and known hypersensitivity to tesamorelin or its ingredients as contraindications. It warns that glucose intolerance or diabetes can develop and calls for glucose and IGF-1 monitoring. These product-specific precautions need clinical assessment; they do not establish the safety of other formulations.4

What does CJC-1295 add to the comparison?

Researchers designed a long-acting CJC-1295 form with a drug-affinity complex, or DAC, to bind a blood protein. Short studies in healthy adults measured growth hormone and IGF-1 after this form. FDA’s 2024 review also described inconsistent naming of CJC-related forms. A result from the DAC form is not proof of an identical duration or outcome for a product labelled without DAC. See DAC, no DAC and product names.78

Can we say one is better for sleep, muscle or fat?

Not from the studies above. They involved different products, populations and outcomes, and were not designed as a direct comparison of these three substances for a shared goal. A hormone rise, a body scan, a cognitive test and a night of sleep are separate outcomes. Discuss the exact product, purpose, evidence and risks with a qualified clinician; do not infer a treatment plan from a similar-sounding name.275